GlassScriptPhysician profile
Amy L Coy
NPI 1326564048
$4,125.11
in general payments reported to CMS, 2019-2025
39 companies · $658 in 2025
The $658 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $912 · 2022: $1,060 · 2023: $922 · 2024: $573 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $871.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $616.17 | 2021-2025 | |
| Lilly USA, LLC | $487.62 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Exact Sciences Corporation | $215.55 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $195.24 | 2021-2024 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $152.08 | 2021-2022 | |
| Lundbeck LLC | $140.30 | 2021-2025 | Rexulti |
| Pfizer INC. | $137.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.84 | 2021-2024 | |
| Glaxosmithkline, LLC. | $86.72 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.07 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $75.81 | 2022 | |
| Amgen INC. | $71.32 | 2022-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $69.83 | 2021 | |
| Astellas Pharma US INC | $64.43 | 2021-2024 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Coy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.